doi: 10.1126/science.316.5831.1550.
Drug safety. Heart attack risk overshadows a popular diabetes therapy
- PMID: 17569830
- DOI: 10.1126/science.316.5831.1550
Item in Clipboard
Drug safety. Heart attack risk overshadows a popular diabetes therapy
Science.
.
No abstract available
Similar articles
-
The painful truth.Eur Heart J. 2010 May;31(10):1284-5. doi: 10.1093/eurheartj/ehq126. Epub 2010 Apr 23. Eur Heart J. 2010. PMID: 20418344 No abstract available.
-
Weighing up the evidence.Nature. 2007 May 31;447(7144):512-3. doi: 10.1038/447512a. Nature. 2007. PMID: 17538581 No abstract available.
-
The rosiglitazone meta-analysis.Rev Cardiovasc Med. 2007 Spring;8(2):123-6. Rev Cardiovasc Med. 2007. PMID: 17603430 Review. No abstract available.
-
Rosiglitazone, marketing, and medical science.BMJ. 2010 Apr 7;340:c1848. doi: 10.1136/bmj.c1848. BMJ. 2010. PMID: 20375091 No abstract available.
-
Thiazolidinediones in type 2 diabetes: a cardiology perspective.Ann Pharmacother. 2008 Oct;42(10):1466-74. doi: 10.1345/aph.1K666. Epub 2008 Sep 2. Ann Pharmacother. 2008. PMID: 18698014 Review.
Cited by
-
Therapeutic interventions and oxidative stress in diabetes.Front Biosci (Landmark Ed). 2009 Jan 1;14(1):192-209. doi: 10.2741/3240. Front Biosci (Landmark Ed). 2009. PMID: 19273063 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
